3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hormone Refractory Prostate Cancer
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
radium Ra 223 dichloride
2
gossypol acetic acid
1
epothilone B
1
cabazitaxel
1
bafetinib
1
Everolimus
1
Denosumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hormone Refractory Prostate Cancer
×
bafetinib
×
Clear all
NCT01215799
2011-12-15
PROACT
CytRx
Phase 2
Completed
23 enrolled